hypersensitivity,
acute renal failure,
pregnancy (I trimester).
Prolongs the effect of barbiturates, enhances the effects of drugs that stimulate the central nervous system, anticonvulsant drugs, the effect of local anesthetics (procaine). Prevents the side effects of the following drugs: phenobarbital, carbamazepine, antipsychotics (neuroleptics).
Action hopantenate acid is enhanced in combination with glycine, xidiphone.
Possible allergic reactions (rhinitis, conjunctivitis, skin rashes).
cognitive impairment in organic brain lesions and neurotic disorders,
as part of the complex therapy of cerebrovascular insufficiency caused by atherosclerotic changes in the blood vessels of the brain, senile dementia (initial form), residual organic brain lesions in adults and the elderly,
cerebral organic insufficiency in patients with schizophrenia (in combination with neuroleptics, antidepressants),
extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (including Huntington's chorea, hepatocerebral dystrophy, Parkinson's disease),
consequences of past neuroinfections and traumatic brain injuries (as part of complex therapy),
correction and prevention (cover-up therapy with simultaneous administration) of side effects of neuroleptics, extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic),
epilepsy with mental retardation (in combination with anticonvulsants),
psychoemotional overload, reduced mental and physical performance, to improve concentration and memorization,
urination disorders: enuresis, daytime urinary incontinence, pollakiuria, imperative urges,
Children:
mental retardation (delay in mental, speech, motor development or a combination of them),
infantile cerebral palsy,
stuttering (mainly clonic form),
epilepsy (as part of combination therapy with anticonvulsants, especially in polymorphic seizures and minor epileptic seizures).
The spectrum of action is associated with the presence of GABA in the structure. The mechanism of action is due to the direct effect of the drug Calcium hopantenate® on the GABAB- receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons. It has anticonvulsant effect, reduces the excitability of the motor with the simultaneous regulation of behavior. Improves mental and physical performance. Promotes normalization of the GABA content in chronic alcohol intoxication and subsequent withdrawal of ethanol. It has an analgesic effect. It is able to inhibit the acetylation reactions involved in the mechanisms of inactivation of novocaine and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated bubble reflex and detrusor tone
When taken orally, it is rapidly absorbed from the gastrointestinal tract. Tmax in the blood plasma is 1 h. The highest concentrations are created in the liver, kidneys, stomach wall, skin. Penetrates through the BBB. It is not metabolized and is excreted unchanged for 48 hours (67.5% of the dose taken - in the urine, 28.5% - in the feces).
Calcium hopantenate
Hopantenic Acid
Inside, 15-30 minutes after eating.
A single dose for adults is usually 2.5-10 ml (0.25–1 g), for children — 2.5–5 ml (0.25–0.5 g).
The daily dose for adults is 15-30 ml (1.5-3 g), for children — 7.5–30 ml (0.75–3 g). The course of treatment is 1-4 months, sometimes up to 6 months. After 3-6 months, a second course of treatment is possible.
Depending on the age and pathology of the nervous system, the following dose range is recommended for children: children of the first year of life-5-10 ml (0.5-1 g) per day, up to 3 years — 5-12.5 ml (0.5–1.25 g) per day,from 3 to 7 years — 7.5–15 ml (0.75–1.5 g), older than 7 years — 10-20 ml (1-2 g).
The treatment strategy involves increasing the dose for 7-12 days, taking the maximum dose for 15-40 days or more, with a gradual reduction in the dose until withdrawal within 7-8 days. The course of treatment is 30-90 days (for some diseases-up to 6 months or more).
Schizophrenia (in combination with psychotropic drugs). From 5 to 30 ml (0.5-3 g) per day. The course of therapy is from 1 to 3 months.
Epilepsy (in combination with anticonvulsants). From 7.5 to 10 ml (0.75-1 g) per day. The course of therapy is up to 1 year or more.
Neuroleptic syndrome, accompanied by extrapyramidal disorders. The daily dose is up to 30 ml (up to 3 g), treatment for several months.
Extrapyramidal hyperkinesis in patients with organic diseases of the nervous system. From 5 to 30 ml (0.5-3 g) per day. The course of treatment is up to 4 months or more.
Consequences of neuroinfections and TBI. From 5 to 30 ml (0.5-3 g) per day.
Recovery of working capacity under increased loads and asthenic conditions. 2.5–5 ml (0.25-0.5 g) 3 times a day.
Disorders of urination. Children — 2.5-5 ml (0.25-0.5 g), the daily dose is 25-50 mg / kg, the course of treatment is 1-3 months, adults-5-10 ml (0.5–1 g) 2-3 times a day.
In conditions of long-term treatment, the simultaneous administration of the drug with other nootropic and stimulating agents is not recommended.
Taking into account the nootropic effect of the drug, its administration is preferably carried out in the morning and afternoon hours.
Inside.
Take 15-30 minutes after meals.
A single dose for adults is 0.5-1 g, for children-0.25-0.5 g, daily-1.5-3 g( for adults), 0.75-3 g (for children). The duration of the course of treatment is from 1 to 4 months, in some cases-up to 6 months. After 3-6 months, a second course of treatment is possible.
Children. Mental disability - 0.5 g 4-6 times a day, daily for 3 months. Delayed speech development - 0.5 g 3-4 times a day for 2-3 months.
Neuroleptic syndrome (as a corrector of the side effect of neuroleptics). Adults-0.5-1 g 3 times a day, children-0.25-0.5 g 3-4 times a day. The duration of the course of treatment is 1-3 months.
Epilepsy. Children — 0.25-0.5 g 3-4 times a day, adults-0.5-1 g 3-4 times a day daily for a long time (up to 6 months).
Hyperkinesis (tics). Children — 0.25-0.5 g 3-6 times a day daily for 1-4 months, adults-1.5-3 g a day daily for 1-5 months.
Disorders of urination. Adults-0.5-1 g 2-3 times a day (daily dose-2-3 g), children-0.25-0.5 g (daily dose-25-50 mg/kg). The duration of the course of treatment is from 2 weeks to 3 months (depending on the severity of the disorders and the therapeutic effect).
Consequences of neuroinfections and traumatic brain injuries. 0.25 g 3-4 times a day.
To restore performance under increased loads and asthenic conditions. 0.25 g 3 times a day.
This dosage form is not recommended for children under 3 years of age.
N06BX Other psychostimulants and nootropic drugs
